Abstract
The antifungal activity of orally active SM-4470, (R)-3-(n-butylthio)-2-(2,4-dichlorophenyl)-1-(imidazole-1-yl)-2-propanol hydrochloride, was compared with that of ketoconazole. SM-4470 showed twofold-higher activity than ketoconazole in the oral treatment of systemic infection with Candida albicans in mice. In addition, SM-4470 was effective against aspergillosis in mice, but ketoconazole was ineffective. The efficacy of SM-4470 was similar to that of ketoconazole in curing experimental candidal vaginitis in rats and trichophytosis in guinea pigs, although its serum concentrations in these animals were lower than those of ketoconazole. These data suggest that SM-4470 may be of value in the treatment of both systemic and superficial fungal infections in humans.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Burgess J. L., Birchall R. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am J Med. 1972 Jul;53(1):77–84. [PubMed] [Google Scholar]
- Heel R. C., Brogden R. N., Carmine A., Morley P. A., Speight T. M., Avery G. S. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs. 1982 Jan-Feb;23(1-2):1–36. doi: 10.2165/00003495-198223010-00001. [DOI] [PubMed] [Google Scholar]
- Holt R. J. Recent developments in antimycotic chemotherapy. Infection. 1974;2(2):95–107. doi: 10.1007/BF01642028. [DOI] [PubMed] [Google Scholar]
- Jevons S., Gymer G. E., Brammer K. W., Cox D. A., Leeming M. R. Antifungal activity of tioconazole (UK-20,349), a new imidazole derivative. Antimicrob Agents Chemother. 1979 Apr;15(4):597–602. doi: 10.1128/aac.15.4.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Petranyi G., Georgopoulos A., Mieth H. In vivo antimycotic activity of naftifine. Antimicrob Agents Chemother. 1981 Mar;19(3):390–392. doi: 10.1128/aac.19.3.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Plempel M., Bartmann K., Büchel K. H., Regel E. BAY b 5097, a new orally applicable antifungal substance with broad-spectrum activity. Antimicrob Agents Chemother (Bethesda) 1969;9:271–274. [PubMed] [Google Scholar]
- Richardson K., Brammer K. W., Marriott M. S., Troke P. F. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother. 1985 May;27(5):832–835. doi: 10.1128/aac.27.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schär G., Kayser F. H., Dupont M. C. Antimicrobial activity of econazole and miconazole in vitro and in experimental candidiasis and aspergillosis. Chemotherapy. 1976;22(3-4):211–220. doi: 10.1159/000221928. [DOI] [PubMed] [Google Scholar]
- Thienpont D., Van Cutsem J., Van Gerven F., Heeres J., Janssen P. A. Ketoconazole -- a new broad spectrum orally active antimycotic. Experientia. 1979 May 15;35(5):606–607. doi: 10.1007/BF01960348. [DOI] [PubMed] [Google Scholar]